File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection

TitlePilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection
Authors
KeywordsDialysis
Hepatitis C
Pegylated interferon
Issue Date2007
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP
Citation
Nephrology, 2007, v. 12 n. 1, p. 11-17 How to Cite?
AbstractAim: Pegylated interferon (PEG-IFN) combined with ribavirin is recommended for the treatment of chronic hepatitis C virus (HCV) infection in patients without renal failure. The optimal treatment of hepatitis C in dialysis patients remains to be established. A high incidence of adverse effects has been observed with conventional interferon and PEG-IFN alpha-2b in dialysis patients. Methods: We conducted a prospective study to investigate the tolerability and efficacy of PEG-IFN alpha-2a (135 μg weekly for 48 weeks) in six dialysis patients with chronic HCV infection. Results: Two patients completed 48 weeks of treatment. Treatment was stopped in three patients (beyond 24 weeks) when they developed unrelated complications, and stopped in one patient due to failure of viral clearance. None required treatment discontinuation due to adverse effects, and PEG-IFN alpha-2a was subjectively well tolerated. Marrow suppression with mild anaemia, leucopenia, or thrombocytopenia remained common. Two patients (infected with genotypes 3a and 1b, respectively) had sustained virological response. Conclusions: Results from this pilot study showed that PEG-IFN alpha-2a appeared relatively well tolerated in dialysis patients with chronic HCV infection, and about one-third of patients could achieve sustained virological response. © 2006 The Authors.
Persistent Identifierhttp://hdl.handle.net/10722/76682
ISSN
2015 Impact Factor: 1.796
2015 SCImago Journal Rankings: 0.894
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.contributor.authorHo, SKNen_HK
dc.contributor.authorTang, CSOen_HK
dc.contributor.authorTse, KCen_HK
dc.contributor.authorLam, MFen_HK
dc.contributor.authorLai, KNen_HK
dc.contributor.authorYung, Sen_HK
dc.date.accessioned2010-09-06T07:23:49Z-
dc.date.available2010-09-06T07:23:49Z-
dc.date.issued2007en_HK
dc.identifier.citationNephrology, 2007, v. 12 n. 1, p. 11-17en_HK
dc.identifier.issn1320-5358en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76682-
dc.description.abstractAim: Pegylated interferon (PEG-IFN) combined with ribavirin is recommended for the treatment of chronic hepatitis C virus (HCV) infection in patients without renal failure. The optimal treatment of hepatitis C in dialysis patients remains to be established. A high incidence of adverse effects has been observed with conventional interferon and PEG-IFN alpha-2b in dialysis patients. Methods: We conducted a prospective study to investigate the tolerability and efficacy of PEG-IFN alpha-2a (135 μg weekly for 48 weeks) in six dialysis patients with chronic HCV infection. Results: Two patients completed 48 weeks of treatment. Treatment was stopped in three patients (beyond 24 weeks) when they developed unrelated complications, and stopped in one patient due to failure of viral clearance. None required treatment discontinuation due to adverse effects, and PEG-IFN alpha-2a was subjectively well tolerated. Marrow suppression with mild anaemia, leucopenia, or thrombocytopenia remained common. Two patients (infected with genotypes 3a and 1b, respectively) had sustained virological response. Conclusions: Results from this pilot study showed that PEG-IFN alpha-2a appeared relatively well tolerated in dialysis patients with chronic HCV infection, and about one-third of patients could achieve sustained virological response. © 2006 The Authors.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEPen_HK
dc.relation.ispartofNephrologyen_HK
dc.subjectDialysisen_HK
dc.subjectHepatitis Cen_HK
dc.subjectPegylated interferonen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntiviral Agents - adverse effects - therapeutic useen_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHepatitis C, Chronic - complications - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInterferon-alpha - adverse effects - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPilot Projectsen_HK
dc.subject.meshPolyethylene Glycols - adverse effects - therapeutic useen_HK
dc.subject.meshRNA, Viral - analysisen_HK
dc.subject.meshRecombinant Proteinsen_HK
dc.subject.meshRenal Dialysisen_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titlePilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1320-5358&volume=12&spage=11&epage=17&date=2007&atitle=Pilot+study+of+pegylated+interferon-alpha+2a+in+dialysis+patients+with+chronic+hepatitis+C+virus+infectionen_HK
dc.identifier.emailChan, TM: dtmchan@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailYung, S: ssyyung@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityYung, S=rp00455en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1797.2006.00662.xen_HK
dc.identifier.pmid17295655-
dc.identifier.scopuseid_2-s2.0-33846999883en_HK
dc.identifier.hkuros130461en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846999883&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume12en_HK
dc.identifier.issue1en_HK
dc.identifier.spage11en_HK
dc.identifier.epage17en_HK
dc.identifier.isiWOS:000244752700004-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK
dc.identifier.scopusauthoridHo, SKN=36839065300en_HK
dc.identifier.scopusauthoridTang, CSO=55225422400en_HK
dc.identifier.scopusauthoridTse, KC=7102609864en_HK
dc.identifier.scopusauthoridLam, MF=35300050600en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridYung, S=22636568800en_HK
dc.identifier.citeulike1089689-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats